In summary, our data provide in vivo evidence for the function of MUC1-CD in the PMI and postpartum breast cancer, suggests that MUC1-CD-targeted therapies toward the window of PMI of corresponding subtypes could be preventive for postpartum breast cancers. Here, MUC1 is linked to breast carcinoma.